This website isn’t supported by Internet Explorer. We recommend that you use a different browser (e.g. Edge, Chrome, Firefox, Safari, or similar) for the best experience of our content.
Science Hub

Welcome to Novo Nordisk Science Hub

The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.


This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.

Are you a healthcare professional?

Speaker - Carolyn Lam
Duke-National University, Singapore, Singapore

Dr Lam is a Professor at Duke-National University of Singapore and Senior Consultant at the National Heart Centre Singapore specializing in heart failure and recognized globally for expertise in heart failure with preserved ejection fraction. She is a world-renown clinical trialist, with her work as part of the global steering committee of the PARAGON and EMPEROR-Preserved trials contributing to the first FDA-approved treatment for HFpEF to date (Entresto Wins First FDA Nod in Hard-to-Treat Type of Heart Failure ( as well as the first robustly positive outcomes trial in HFpEF to date. Her leadership in the field is recognized in her appointment to the 2021 European Society of Cardiology Heart Failure Guidelines Task Force. She is a recipient of the NMRC Senior Investigator Clinician Scientist Award, Programme Lead of A*STaR’s Asian neTwork for Translational Research and Cardiovascular Trials (ATTRaCT), Principal Investigator of ASIAN-HF (multinational study across 11 Asian countries), and Executive Committee member/ lead of multiple global clinical trials. She has published >350 articles in journals including NEJM, JAMA, Lancet, Circulation, and European Heart Journal; and has been recognized in the Clarivate Highly cited Researcher 2021 in the field of Clinical Medicine( and as a World Expert by Expertscape’s PubMed-based algorithms (top 0.1%of scholars writing about Heart Failure over the past 10 years; Heart Failure: Worldwide - She serves as Associate Editor for Circulation and the European Journal of Heart Failure. Dr Lam is heard weekly on the global podcast “Circulation On The Run” and seen regularly on television as the Resident Doctor of “Body and Soul” by MediaCorp Singapore.